DE60137264D1 - Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc) - Google Patents

Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)

Info

Publication number
DE60137264D1
DE60137264D1 DE60137264T DE60137264T DE60137264D1 DE 60137264 D1 DE60137264 D1 DE 60137264D1 DE 60137264 T DE60137264 T DE 60137264T DE 60137264 T DE60137264 T DE 60137264T DE 60137264 D1 DE60137264 D1 DE 60137264D1
Authority
DE
Germany
Prior art keywords
sclc
surface antigens
lung cancer
monoclonal antibodies
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60137264T
Other languages
English (en)
Inventor
Cohava Gelber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImmunoCellular Therapeutics Ltd
Original Assignee
ImmunoCellular Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImmunoCellular Therapeutics Ltd filed Critical ImmunoCellular Therapeutics Ltd
Application granted granted Critical
Publication of DE60137264D1 publication Critical patent/DE60137264D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
DE60137264T 2000-11-02 2001-11-01 Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc) Expired - Lifetime DE60137264D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24534000P 2000-11-02 2000-11-02
PCT/US2001/048403 WO2002057741A2 (en) 2000-11-02 2001-11-01 Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)

Publications (1)

Publication Number Publication Date
DE60137264D1 true DE60137264D1 (de) 2009-02-12

Family

ID=22926277

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60137264T Expired - Lifetime DE60137264D1 (de) 2000-11-02 2001-11-01 Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)

Country Status (9)

Country Link
US (5) US7183389B2 (de)
EP (1) EP1350085B1 (de)
JP (1) JP4287147B2 (de)
AT (1) ATE419516T1 (de)
AU (1) AU2002246668A1 (de)
CA (1) CA2427643C (de)
DE (1) DE60137264D1 (de)
IL (2) IL155611A0 (de)
WO (1) WO2002057741A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060057147A1 (en) 2002-10-04 2006-03-16 Mitsubishi Pharma Corporation Antibody recognizing antibody
US7777006B2 (en) 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
US20040137538A1 (en) * 2003-01-10 2004-07-15 Bradford Sherry A. Cancer comprehensive assay kit for identifying cancer protein patterns
US20040137539A1 (en) * 2003-01-10 2004-07-15 Bradford Sherry A. Cancer comprehensive method for identifying cancer protein patterns and determination of cancer treatment strategies
WO2004094612A2 (en) * 2003-04-22 2004-11-04 A & G Pharmaceutical, Inc. Cancer specific monoclonal antibodies
EP1960434B1 (de) * 2005-12-08 2012-07-11 Medarex, Inc. Humane monoklonale antikörper gegen fucosyl-gm1 und verfahren zur anwendung von anti-fucosyl-gm1
US20100081927A1 (en) * 2008-09-29 2010-04-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Histological facilitation systems and methods
US20100081915A1 (en) * 2008-09-29 2010-04-01 Searete Llc, Alimited Liability Corporation Of The State Of Delaware Histological facilitation systems and methods
US20100081926A1 (en) * 2008-09-29 2010-04-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Histological facilitation systems and methods
US20100081928A1 (en) * 2008-09-29 2010-04-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Histological Facilitation systems and methods
US20100081924A1 (en) * 2008-09-29 2010-04-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Histological facilitation systems and methods
US20100081916A1 (en) * 2008-09-29 2010-04-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware. Histological facilitation systems and methods
WO2010098471A1 (ja) 2009-02-27 2010-09-02 株式会社バイオマトリックス研究所 がん細胞を用いた免疫方法
JPWO2012026615A1 (ja) 2010-08-25 2013-10-28 株式会社オーダーメードメディカルリサーチ がん細胞を用いた抗体の製造方法
EP3199542B1 (de) * 2010-09-17 2018-11-14 National Institute of Advanced Industrial Science and Technology Lungenkrebs-identifikationsmarker
US9447187B2 (en) 2011-02-03 2016-09-20 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
WO2012167163A2 (en) 2011-06-03 2012-12-06 University Of South Alabama Methods and compositions for detecting endometrial or ovarian cancer
MX343324B (es) * 2011-07-06 2016-11-01 Nestec Sa Ensayos para detectar auto anticuerpos neutralizadores de la terapia biologica con tnf alpha.
WO2019126536A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Humanized anti-cd200 antibodies and uses thereof
US11964121B2 (en) 2021-10-13 2024-04-23 Satio, Inc. Mono dose dermal patch for pharmaceutical delivery
US11877848B2 (en) 2021-11-08 2024-01-23 Satio, Inc. Dermal patch for collecting a physiological sample

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4585742A (en) * 1983-12-14 1986-04-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibody with specificity to human small cell carcinoma and use thereof
US5344919A (en) * 1987-02-19 1994-09-06 The Scripps Research Institute Integrin from human epithelial cells
WO1994006929A1 (en) * 1992-09-17 1994-03-31 Merck Patent Gmbh Small cell lung carcinoma specific antibody and antigen
EP0961780B1 (de) 1997-02-12 2007-04-11 Electrophoretics Limited Proteinmarker für lungenkrebs und deren verwendung
US6162616A (en) 1997-04-16 2000-12-19 Millennium Pharmaceuticals, Inc. Multidrug resistance-associated polypeptide

Also Published As

Publication number Publication date
US20050069964A1 (en) 2005-03-31
WO2002057741A3 (en) 2002-11-28
EP1350085A2 (de) 2003-10-08
US7183389B2 (en) 2007-02-27
US7687607B2 (en) 2010-03-30
US20050063977A1 (en) 2005-03-24
AU2002246668A1 (en) 2002-07-30
IL155611A0 (en) 2003-11-23
CA2427643C (en) 2014-04-15
WO2002057741A2 (en) 2002-07-25
JP2004517885A (ja) 2004-06-17
US20020137109A1 (en) 2002-09-26
EP1350085A4 (de) 2005-01-19
JP4287147B2 (ja) 2009-07-01
US20090035316A1 (en) 2009-02-05
CA2427643A1 (en) 2002-07-25
EP1350085B1 (de) 2008-12-31
US7435554B2 (en) 2008-10-14
ATE419516T1 (de) 2009-01-15
IL155611A (en) 2010-05-31
US20090041660A1 (en) 2009-02-12
US7435415B2 (en) 2008-10-14

Similar Documents

Publication Publication Date Title
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
WO2002059604A3 (en) Diagnosis and treatment of multiple sclerosis
MXPA02011379A (es) Ensayo de deteccion de genes para mejorar la probabilidad de una respuesta efectiva a terapia de cancer con el antagonista erbb.
NZ513498A (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
ES2120416T3 (es) Inhibidores del crecimiento tumoral derivados de tejidos, metodos de preparacion y usos de dichos inhibidores.
PT991421E (pt) Deteccao e modulacao das iap e naip para o diagnostico e tratamento de doenca proliferativa
WO2003087831A3 (en) Proteins involved in breast cancer
WO2004067570A3 (en) Prostate cancer diagnosis and treatment
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
NZ330887A (en) Monoclonals and polyclonals antibodies for the diagnosis of breast cancer
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
CY1108182T1 (el) Μεσα εντοπισμου του παθολογικου μετασχηματισμου της πρωτεϊνης app και εφαρμογες τους
NO994932L (no) Blandinger og fremgangsmåter for behandling og diagnose av brystkreft
IL151448A0 (en) Proteins
WO2004007770A3 (en) Method for diagnosis of intestinal-type gastric tumors
WO2003030725A3 (en) Pancreatic cancer diagnosis and therapies
ATE466938T1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
WO2004040312A3 (fr) Proceded de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
MXPA05006034A (es) Proteina de duplicacion.
DE60109359D1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
AU2002367317A1 (en) Psoriasin expression by breast epithelial cells
WO2005106039A8 (en) Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer
MXPA01010186A (es) Composiciones y metodos para el tratamiento y diagnostico de cancer de mama.
WO2001004343A3 (en) A method for determining the prognosis of cancer patients by measuring levels of bag expression
WO2001062785A3 (en) Protein and gene and their use for diagnosis and treatment of schizophrenia

Legal Events

Date Code Title Description
8364 No opposition during term of opposition